Regenerating matrix-based therapy for chronic wound healing: a prospective within-subject pilot study
- 16 November 2010
- journal article
- clinical trial
- Published by Wiley in International Wound Journal
- Vol. 8 (1) , 85-95
Abstract
The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan sulphate mimetic (CACIPLIQ20) improves chronic wound healing. The design of this article is a prospective within-subject study. The setting was an urban hospital. Patients were 16 African-American individuals (mean age 42 years) with 22 wounds (mean duration 2.5 years) because of either pressure, diabetic, vascular or burn wounds. Two participants each were lost to follow-up or removed because of poor compliance, resulting in 18 wounds analysed. Sterile gauze was soaked with CACIPLIQ20 saline solution, placed on the wound for 5 min, then removed twice weekly for 4 weeks. Wounds were otherwise treated according to the standard of care. Twenty-two percent of wounds fully healed during the treatment period. Wounds showed a 15.2-18.1% decrease in wound size as measured by the vision engineering research group (VERG) digital wound measurement system and total PUSH scores, respectively, at 4 weeks (P = 0.014 and P = 0.003). At 8 weeks there was an 18-26% reduction in wound size (P = 0.04) in the remaining patients. Wound-related pain measured by the visual analogue pain scale and the wound pain scale declined 60% (P = 0.024) and 70% (P = 0.001), respectively. Patient and clinician satisfaction remained positive throughout the treatment period. It is concluded that treatment with CACIPLIQ20 significantly improved wound-related pain and may facilitate wound healing. Patient and clinician satisfaction remained high throughout the trial.Keywords
This publication has 52 references indexed in Scilit:
- Differential Effect Triggered by a Heparan Mimetic of the RGTA Family Preventing Oral Mucositis Without Tumor ProtectionInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- The management of neuropathic ulcers of the foot in diabetes by shock wave therapyBMC Musculoskeletal Disorders, 2009
- RGTA OTR 4120, a heparan sulfate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full‐thickness excisional woundsWound Repair and Regeneration, 2008
- Extracellular Matrix as a Strategy for Treating Chronic WoundsAmerican Journal of Clinical Dermatology, 2007
- The management of patients’ pain in wound careNursing Standard, 2005
- The use of topical opioids to relieve pressure ulcer painNursing Standard, 2005
- Heparanase accelerates wound angiogenesis and wound healing in mouse and rat modelsThe FASEB Journal, 2005
- Structurally different RGTAs modulate collagen‐type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor‐2 or transforming growth factor‐β1The FASEB Journal, 2004
- An in vitro examination of an extracellular matrix scaffold for use in wound healingInternational Journal of Experimental Pathology, 2002
- New agents for the treatment of infarcted myocardiumThe FASEB Journal, 2000